Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$119.37

1.36 (1.15%)

, SNY

Sanofi

$51.63

0.46 (0.90%)

06:30
01/13/20
01/13
06:30
01/13/20
06:30

Drugmakers trying out new ways to pay for expensive drug treatments, WSJ reports

Drugmakers are trying out new reimbursement models that depend on collecting more and better patient data, The Wall Street Journal's Jared S. Hopkins reports. According to the report, Alnylam Pharmaceuticals (ALNY) will now only charge full value for a nearly $600,000 new rare-disease drug only if a patient gets a benefit similar to what was seen in clinical testing, and it will make the drug cheaper for insurers if they cover more patients than expected. Meanwhile, Sanofi (SNY) is offering $99-a-month subscriptions for insulin, while Novartis (NVS), which sells a gene therapy at $2.1M, is giving insurers the opportunity to pay over five years. Earlier this month, drugmakers raised prices of hundreds of prescription medicines, the Journal previously reported. Reference Link

ALNY

Alnylam

$119.37

1.36 (1.15%)

SNY

Sanofi

$51.63

0.46 (0.90%)

NVS

Novartis

$93.87

-0.88 (-0.93%)

  • 13

    Jan

  • 13

    Jan

  • 04

    Feb

  • 10

    Feb

  • 13

    Feb

ALNY Alnylam
$119.37

1.36 (1.15%)

12/17/19
PIPR
12/17/19
NO CHANGE
Target $155
PIPR
Overweight
Alnylam price target raised to $155 from $145 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff maintained an Overweight rating on Alnylam Pharmaceuticals and raised his price target on the shares to $155 from $145 after the company reported "positive" Phase III ILLUMINATE-A data on lumasiran in primary hyperoxaluria type 1. Tenthoff said he is "confident" in the treatment getting approval in the U.S. by year end 2020 and in Europe in 2021 and he forecasts lumasirin sales of $8M in 2020 and $85M in 2021. The analyst also noted that ONPATTRO and GIVLAARI launches are "progressing" to drive 2020 sales.
12/18/19
CANT
12/18/19
NO CHANGE
Target $176
CANT
Overweight
Alnylam price target raised to $176 from $159 at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young raised her price target for Alnylam Pharmaceuticals to $176 from $159 saying the company reported a "very clean" positive top-line readout for lumasiran. The analyst finds it notable that lumasiran is the company's fourth pivotal RNAi readout in the past two years and will be the third wholly owned commercial product after Onpattro and recently approved Givlaari. She thinks the positive update adds to Alnylam's recent momentum heading into 2020, as its "rapid transition to a full fledged commercial company with a robust pipeline continues." Young reiterates an Overweight rating on Alnylam.
11/25/19
STFL
11/25/19
NO CHANGE
Target $136
STFL
Buy
Alnylam one of few mid-caps with 'plausible large-cap aspirations,' says Stifel
Stifel analyst Paul Matteis raised his price target on Alnylam shares to $136 from $126 citing earlier than expected Givosiran approval, higher than anticipated pricing and "promising advancements" in the company's early stage pipeline. A major theme of the company's analyst day was Alnylam's confidence in pursuing larger, non-orphan indications, said Matteis, who also noted that 2019 "was framed as a peak operating loss year" although no guidance was given during the event. The analyst, who sees a "compelling case" for Alnylam being "one of the few mid-caps with plausible large-cap aspirations," keeps a Buy rating on the stock.
11/25/19
BMOC
11/25/19
NO CHANGE
Target $143
BMOC
Outperform
Alnylam price target raised to $143 from $138 at BMO Capital
BMO Capital analyst Do Kim raised his price target on Alnylam to $143 and kept his Buy rating after its R&D Day highlighted the company's commercial and pipeline plans. With Lumasiran Phase 3 trial data expected next month and his estimated "likely approval" for the drug in late-2020, the analyst also adds its projected revenue to his model, assigning an 80% probability-of-success to the program while also citing Alnylam's global Onpattro expansion driving further top-line growth.
SNY Sanofi
$51.63

0.46 (0.90%)

01/08/20
STFL
01/08/20
NO CHANGE
STFL
Stifel names Momenta and Principia top 2020 SMID cap Biotech picks
Stifel analyst Derek Archila named Momenta Pharmaceuticals (MNTA) and Principia Biopharma (PRNB) his top 2020 picks in the SMID cap Biotech space. The analyst also added Momenta to his firm's Select List while removing Heron Therapeutics (HRTX). Momenta's anti-FcRn candidate, nipocalimab, is mechanistically de-risked and has a high probability of success in demonstrating positive proof-of-concept in its Phase 2 myasthenia gravis study in mid-2020, Archila tells investors in a research note. Further, he believes the "broad potential" of the program is not completely factored into the stock, which could lead to "meaningful upside." Archila thinks Principia's first half of 2020 update on whether it decides to opt in to more favorable economics on PRN2246, a BTK inhibitor being developed in multiple sclerosis by partner Sanofi (SNY), could be a "significant value creating event." Share upside of 50%-75% from current levels is possible depending on the scenario, says the analyst. He keeps a Buy rating on Heron despite removing the shares from the Select List. Archila expects HTX-011 to get approved in March 2020 and believes it is a launch investors should own.
01/06/20
01/06/20
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL) upgraded to Buy from Hold at Pivotal Research with analyst Michael Levine saying the shares will outperform the other large cap Internet names in 2020 as estimates move higher. 2. Citi (C) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Richard Ramsden saying the market is overly pessimistic on Citi's revenue growth inflection, targeted expense savings, and outlook for credit costs, given the improvement in the risk profile of its international loan book. 3. Salesforce (CRM) upgraded to Top Pick from Outperform at RBC Capital with analyst Alex Zukin citing what he sees as significant upside potential in 2020. 4. Sanofi (SNY) upgraded to Overweight from Neutral at JPMorgan with analyst Richard Vosser saying Sanofi should start to close the valuation gap relative to peers in 2020. 5. Nokia (NOK) upgraded to Strong Buy from Outperform at Raymond James with analyst Simon Leopold citing his view of the risk-reward and conclusion that its prospect for recovery appears promising. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/06/20
JPMS
01/06/20
UPGRADE
Target $103
JPMS
Overweight
JPMorgan upgrades Sanofi to Overweight on 'unjustified' valuation gap
JPMorgan analyst Richard Vosser upgraded Sanofi (SNY) to Overweight from Neutral with a price target of EUR 103, up from EUR 81. Sanofi should start to close the valuation gap relative to peers in 2020, Vosser tells investors in a research note. The analyst believes the stock's current multiple of 12.6 times is "unjustified," especially when Novartis (NVS) trades on 14.3 times for a similar growth profile of 2.7%. He also also sees the potential for earnings upgrades driven by Dupixent.
NVS Novartis
$93.87

-0.88 (-0.93%)

12/18/19
HCWC
12/18/19
NO CHANGE
Target $4
HCWC
Buy
Aduro Biotech price target lowered to $4 from $7 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis lowered his price target for Aduro Biotech (ADRO) to $4 from $7 after the company announced Novartis' (NVS) decision to remove ADU-S100 from its portfolio. While acknowledging the announcement is perceived as an overall negative, the analyst notes that Novartis remains committed to targeting the pathway. As such, he has no expectation that the company is going to alter the terms of its partnership with Aduro. Pantginis keeps a Buy rating on Aduro Biotech.
12/16/19
EVER
12/16/19
DOWNGRADE
Target $381
EVER
In Line
Evercore downgrades Regeneron on Eylea risk from Beovu
Evercore ISI analyst Joshua Schimmer downgraded Regeneron Pharmaceuticals (REGN) to In Line from Outperform with an unchanged price target of $381. Early feedback on Novartis' (NVS) Beovu is stronger than expected, which creates risk of erosion for Regeneron's Eylea in 2020 and 2021, Schimmer tells investors in a research note. He now believes Eylea's erosion will be faster than anticipated and "dominate investor dialogue as investors check with specialists."
12/16/19
12/16/19
NO CHANGE

Novartis ends development of fevipiprant in asthma after Phase III failure
Novartis announced topline results from its pivotal global Phase III LUSTER-11and LUSTER-22studies exploring the efficacy and safety of the investigational oral, once-daily, DP2receptor antagonist fevipiprant. The pooled analyses of the LUSTER trials did not meet the clinically relevant threshold for reduction in rate of moderate -to-severe exacerbation compared to placebo over a 52-week treatment period for either of the doses. The studies included patients who had inadequately controlled moderate-to-severe asthma despite receiving inhaled mid-to-high dose corticosteroids and at least one additional controller. The totality of these results do not support further development of fevipiprant in asthma, Novartis said in a statement. "While the results of the LUSTER studies with fevipiprant are disappointing, they meaningfully contribute to our understanding of the DP2pathway in asthma. We are incredibly grateful to all the patients, their families and the investigators who participated in the studies and contributed greatly to this research," said John Tsai, Head Global Drug Development and Chief Medical Officer, Novartis.

TODAY'S FREE FLY STORIES

WNS

WNS Holdings

$70.73

1.92 (2.79%)

08:46
01/17/20
01/17
08:46
01/17/20
08:46
Recommendations
WNS Holdings analyst commentary  »

WNS Holdings price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GTT

GTT Communications

$13.50

0.06 (0.45%)

, SKT

Tanger Factory

$15.43

-0.06 (-0.39%)

08:45
01/17/20
01/17
08:45
01/17/20
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

GTT

GTT Communications

$13.50

0.06 (0.45%)

SKT

Tanger Factory

$15.43

-0.06 (-0.39%)

SDC

SmileDirectClub

$13.22

-0.5 (-3.64%)

BLDP

Ballard Power

$11.05

0.44 (4.15%)

TLRD

Tailored Brands

$4.29

0.045 (1.06%)

MNK

Mallinckrodt

$5.22

0.74 (16.52%)

IRBT

iRobot

$55.84

2.55 (4.79%)

AMJ

American Medical Laboratories Inc

$22.77

0.06 (0.26%)

NK

NantKwest

$7.39

2.1 (39.70%)

WVE

Wave Life Sciences

$8.10

0.13 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 09

    Mar

08:45
01/17/20
01/17
08:45
01/17/20
08:45
General news
U.S. December housing starts surged 16.9% to a 1.608 M pace »

U.S. December housing…

08:45
01/17/20
01/17
08:45
01/17/20
08:45
General news
FX Action: The dollar »

FX Action: The dollar…

08:45
01/17/20
01/17
08:45
01/17/20
08:45
General news
Breaking General news story  »

Philadelphia Federal…

08:45
01/17/20
01/17
08:45
01/17/20
08:45
General news
Breaking General news story  »

Philadelphia Federal…

08:44
01/17/20
01/17
08:44
01/17/20
08:44
Conference/Events
JPMorgan U.S. telecom & semis analysts hold an analyst/industry conference call »

U.S. Telecom &…

LUV

Southwest

$55.30

0.26 (0.47%)

08:43
01/17/20
01/17
08:43
01/17/20
08:43
Downgrade
Southwest rating change  »

Deutsche downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

DE

Deere

$175.53

2.59 (1.50%)

08:42
01/17/20
01/17
08:42
01/17/20
08:42
Recommendations
Deere analyst commentary  »

Expectation of 2020…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WING

Wingstop

$87.67

-3.78 (-4.13%)

08:41
01/17/20
01/17
08:41
01/17/20
08:41
Recommendations
Wingstop analyst commentary  »

Wingstop price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:38
01/17/20
01/17
08:38
01/17/20
08:38
Conference/Events
Federal Reserve Board of Governors Vice Chairman speaks at a meeting »

Randal Quarles, Vice…

CSX

CSX

$76.75

1.76 (2.35%)

08:37
01/17/20
01/17
08:37
01/17/20
08:37
Recommendations
CSX analyst commentary  »

CSX price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:36
01/17/20
01/17
08:36
01/17/20
08:36
Conference/Events
Federal Reserve Bank of Philadelphia president participates in a discussion »

Federal Reserve Bank of…

IPIX

Innovation Pharmaceuticals

$0.00

(0.00%)

08:36
01/17/20
01/17
08:36
01/17/20
08:36
Hot Stocks
Innovation Pharmaceuticals announces dose escalation in Phase 1 trial »

Innovation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCDBF

CCL Industries

$0.00

(0.00%)

08:35
01/17/20
01/17
08:35
01/17/20
08:35
Hot Stocks
CCL Industries announces two bolt-on acquisitions for Avery »

CCL Industries announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$18.62

0.695 (3.88%)

08:34
01/17/20
01/17
08:34
01/17/20
08:34
Recommendations
Gap analyst commentary  »

Gap price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

08:34
01/17/20
01/17
08:34
01/17/20
08:34
Conference/Events
UBS leisure analyst to hold an analyst/industry conference call »

Leisure, Gaming &…

PRGS

Progress Software

$47.54

2.25 (4.97%)

08:34
01/17/20
01/17
08:34
01/17/20
08:34
Recommendations
Progress Software analyst commentary  »

Progress Software price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHX

Panhandle Oil & Gas

$9.40

-0.02 (-0.21%)

08:33
01/17/20
01/17
08:33
01/17/20
08:33
Hot Stocks
Panhandle Oil & Gas appoints Interim CEO Chad Stephens as CEO »

Panhandle appointed Chad…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSA

Comcast

$46.86

0.56 (1.21%)

08:32
01/17/20
01/17
08:32
01/17/20
08:32
Recommendations
Comcast analyst commentary  »

JPMorgan sees 32M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

WMT

Walmart

$115.89

0.6 (0.52%)

08:30
01/17/20
01/17
08:30
01/17/20
08:30
Conference/Events
Cowen retail analyst to hold an analyst/industry conference call »

Retail Analyst Chen,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARQL

ArQule

$19.99

(0.00%)

08:30
01/17/20
01/17
08:30
01/17/20
08:30
Options
One option delisting on January 17th »

Option delistings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPZ

Domino's Pizza

$287.30

-0.6 (-0.21%)

08:28
01/17/20
01/17
08:28
01/17/20
08:28
Recommendations
Domino's Pizza analyst commentary  »

Domino's Pizza price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

OPRT

Oportun Financial

$23.09

0.19 (0.83%)

08:26
01/17/20
01/17
08:26
01/17/20
08:26
Downgrade
Oportun Financial rating change  »

Oportun Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:26
01/17/20
01/17
08:26
01/17/20
08:26
Conference/Events
Cowen Washington policy strategist to hold an analyst/industry conference call »

Washington Policy…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.